Creative Biolabs bridges the gap between systemic inflammation and clinical outcomes by providing a comprehensive "immune snapshot" of candidate-host interactions. Utilizing multi-parametric signatures rather than single-analyte data, our platform identifies primary non-responders early in development. We integrate circulating signatures to monitor the "crosstalk" between local disease environments and peripheral circulation, a critical step for predicting efficacy and cytokine-related toxicity in biologics and cell therapies. This proprietary framework distinguishes true disease progression from pseudoprogression, ensuring viable candidates are not prematurely discarded.

Scientific Foundation of Systemic Immune Monitoring

The assessment of circulating immune signatures involves quantifying soluble mediators and cellular phenotypes in peripheral blood to reflect the local disease environment. Landmark research has confirmed that composite cytokine clusters, such as the combination of IL-6, IL-10, and IL-8, are superior to single markers for predicting overall survival and treatment resistance in oncology. Furthermore, evidence now connects these systemic signatures to neuro-psychiatric conditions, demonstrating that peripheral T-cell polarization and specific growth factors like FGF-19 can serve as markers for central inflammation. Creative Biolabs leverages these insights to provide a comprehensive analytical service that supports multi-disciplinary drug development.

Multi-Dimensional High-Plex Cytokine & Immune Phenotyping Solutions

Creative Biolabs provides a multi-dimensional analytical platform tailored to the specific needs of oncology, neurology, and inflammatory disease research. Our offerings go beyond simple quantification; we provide biological interpretation based on current scientific literature.

Uncover the hidden immune drivers in your cohort – Request a Specialist Consultation

Workflow

To ensure the highest data integrity and biological relevance, our workflow is designed for transparency and precision.

Publication

This review comprehensively examines circulating biomarkers as predictors of response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). Beyond tissue-based PD-L1 expression and tumor mutational burden, the authors explore liquid biopsy-derived analytes, including circulating tumor DNA, circulating tumor cells, microRNAs, extracellular vesicles, peripheral immune cells, and cytokines. These emerging biomarkers offer potential for dynamic, minimally invasive monitoring of ICI response and resistance, aiming to improve patient selection and treatment outcomes.

Fig.1 The liquid biopsy landscape: a multifaceted source of cancer biomarkers.¹

Why Choose Us?

Creative Biolabs stands at the forefront of immunotherapy research, leveraging over 20 years of experience to transform raw discovery into actionable drug leads. Our platform prioritizes precision stratification by integrating etiological backgrounds and demographic variables, ensuring biomarker robustness and reproducibility across diverse patient cohorts. Utilizing high-plex customization, we simultaneously analyze over 100+ analytes, maximizing data extraction from limited materials. This validated methodology is backed by published data proving that multi-analyte signatures significantly outperform single-biomarker approaches in predicting overall survival. Our commitment to scientific excellence provides the high-resolution granularity required to evaluate therapeutic efficacy and accelerate clinical development.

Accelerate your research decision-making with the Creative Biolabs advantage – Get a Precision Quote Today

FAQs

Q1: How do you ensure the stability of low-abundance cytokines?

A1: We utilize ultrasensitive detection technologies and high-affinity antibody pairs capable of detecting analytes at sub-picogram levels, ensuring accuracy in samples with low inflammatory signals.

Q2: Can this service help distinguish pseudoprogression?

A2: Yes. By monitoring longitudinal shifts in IL-6 and IL-10 dynamics alongside cellular markers, we provide data that helps distinguish transient inflammatory influx from true tumor escape.

Q3: Is it possible to customize panels for specific diseases?

A3: Absolutely. Creative Biolabs offers fully customizable panels for 100+ analytes and can adapt baselines based on etiology (e.g., viral vs. metabolic backgrounds) to ensure precise stratification.

Customer Review

• Enhanced Precision in Neuro-Inflammation
  The specificity of the Tc17/Treg ratio analysis provided by Creative Biolabs significantly improved our neuro-inflammatory research. - Dr. Sarah W***n
• Expertise in Etiology-Based Stratification
  Their ability to account for specific immune baselines in our HCC project was a game-changer for our biomarker validation. - Prof. Elena K***v

Related Services

To further support your goals, Creative Biolabs offers several complementary services:

How to Contact Creative Biolabs

Creative Biolabs provides a premier, data-driven service to navigate the complexities of modern immunotherapy. From high-plex quantitation to sophisticated bioinformatics, we provide the insights needed to accelerate your drug to market.

Contact Our Senior Scientists for More Information and to Discuss Your Project

Reference

1. Spagnolo, C. C., et al. "Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?" Crit Rev Oncol Hematol 197 (2024): 104332. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.critrevonc.2024.104332